Haleon (HLN) Cost of Revenue (2021 - 2025)

Haleon's (HLN) quarterly Cost of Revenue came in at $2.6 billion in Q4 2025, down 35.43% on a QoQ basis from $4.1 billion in Q4 2023.

Haleon (HLN) Cost of Revenue (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of Cost of Revenue data on file, last reported at $2.6 billion in Q4 2025.

Quarterly Cost of Revenue changed N/A year-over-year to $2.6 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.4 billion (changed N/A YoY) and the FY2025 annual result came in at $5.3 billion, down 6.77% from the prior year.
Cost of Revenue eased to $2.6 billion in Q4 2025, from $4.1 billion in the prior quarter.
In the past five years, Cost of Revenue ranged from a high of $4.1 billion in Q4 2023 to a low of $1.3 billion in Q2 2023.
A 4-year average of $2.7 billion and a median of $2.6 billion in 2025 frame the typical range for Cost of Revenue.
Annual changes were most pronounced in 2022 — Cost of Revenue decreased 1.49% — and 2023, when it gained 13.45%.
Tracing HLN's Cost of Revenue over 4 years: stood at $3.6 billion in 2021, then retreated by 1.49% to $3.6 billion in 2022, then climbed by 13.45% to $4.1 billion in 2023, then slumped by 35.43% to $2.6 billion in 2025.
The last three Cost of Revenue figures came in at $2.6 billion (Q4 2025), $4.1 billion (Q4 2023), and $1.3 billion (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Haleon	43.76 Bn	42.80 Bn	-	-
2	Teva Pharmaceutical Industries	43.05 Bn	39.39 Bn	2.15 Bn	1.99 Bn
3	Zoetis	31.51 Bn	29.84 Bn	1.05 Bn	673.00 Mn
4	Takeda Pharmaceutical	28.70 Bn	22.90 Bn	5.10 Bn	2.55 Bn
5	United Therapeutics	22.27 Bn	19.61 Bn	683.80 Mn	99.50 Mn
6	Viatris	18.83 Bn	17.95 Bn	1.46 Bn	2.30 Bn
7	Neurocrine Biosciences	15.65 Bn	15.26 Bn	935.80 Mn	23.20 Mn
8	Elanco Animal Health	12.06 Bn	11.53 Bn	798.00 Mn	570.00 Mn
9	Dr Reddys Laboratories	10.12 Bn	9.95 Bn	-	-
10	Alkermes	8.27 Bn	7.61 Bn	397.90 Mn	98.11 Mn

Download Data